BioCentury
ARTICLE | Clinical News

BL-8040: Phase IIb started

September 28, 2015 7:00 AM UTC

BioLineRx began the double-blind, placebo-controlled, German Phase IIb BLAST trial to evaluate 1.25 mg/kg subcutaneous BL-8040 once daily on days 1-5 plus twice-daily IV cytarabine on days 1, 3 and 5 ...